{{'Sun, 30 Mar 2025 10:00:00 -0400' | dateFormatUsFilter}}
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Read more
{{'Sat, 29 Mar 2025 14:30:00 -0400' | dateFormatUsFilter}}
Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
Read more
{{'Sat, 29 Mar 2025 10:30:00 -0400' | dateFormatUsFilter}}
Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025
Read more
Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.